Prescribing Lorazepam for IUD Insertion: Pilot Feasibility Study

Launched by UNIVERSITY OF WISCONSIN, MADISON · Jul 3, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring whether taking lorazepam, a medication that can help reduce anxiety, before getting an intrauterine device (IUD) inserted can make the experience less painful and more comfortable for women. The study will involve 25 adult females who are scheduled for IUD insertion at a specific clinic. Researchers will ask participants to rate their anxiety and pain levels before and after the procedure to see how effective lorazepam is in helping to manage these feelings.

To be eligible for this trial, participants must be undergoing IUD insertion and agree to complete surveys about their anxiety and pain. It's important that they have someone to drive them to and from their appointment if they take lorazepam, as it can make them feel drowsy. Participants will also need to provide consent electronically. It's worth noting that certain individuals, such as those with a history of substance use or who are already on specific medications, will not be able to participate. Overall, this study aims to find out if lorazepam can be a helpful option for women facing the anxiety and discomfort of IUD insertion.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Participants who undergo IUD insertion and complete the visual analogue scales to rate their anxiety and pain level prior to the procedure and after the procedure.
• • Participants must have a driver take them to their appointment if they take lorazepam prior to their arrival at the clinic.
• • Participants must have a driver take them home after the procedure as well.
• • Participants must consent to email communication since they will sign the consent forms electronically
• Exclusion Criteria:
• • Participants who do not show up for their appointment.
• • Participants who receive cervical blocks or other analgesic method during IUD insertion.
• • Participants who have a history of substance use disorder.
• • Participants who are taking medications with a central nervous system (CNS) depressant effect (ex: opioids, benzodiazepines).
• • Participants who are not able to sign an electronic consent form.
• • Participants who do not have a driver to take them to their appointment and to take them home after the procedure.
• • Participants who do not agree to sign consent forms electronically.